Shee K, Jiang A, Varn FS, et al. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. FASEB J. 2019;33(2):1644-1657. doi:10.1096/fj.201801241R.

Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546(7658):426-430. doi:10.1038/nature22797.

Giltnane JM, Hutchinson KE, Stricker TP, et al. Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9(402). doi:10.1126/scitranslmed.aai7993.

Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018;28(11):911-925. doi:10.1016/j.tcb.2018.07.002.

Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-475. doi:10.1038/nature23465.

Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017;23(18):5658. doi:10.1158/1078-0432.CCR-17-1819.

Bandopadhayay P, Piccioni F, O’Rourke R, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019;10(1):2400. doi:10.1038/s41467-019-10307-9.

Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711.

Gong Y, Zack TI, Morris LGT, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014;46(6):588-94. doi:10.1038/ng.2981.

Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature. 2014;510(7506):547-51. doi:10.1038/nature13267.